← 返回

卵巢癌中可变剪接景观的综合特征分析揭示了与肿瘤免疫微环境相关的新事件

英文原题:Comprehensive characterization of the alternative splicing landscape in ovarian cancer reveals novel events associated with tumor-immune microenvironment.

查看英文原题

Comprehensive characterization of the alternative splicing landscape in ovarian cancer reveals novel events associated with tumor-immune microenvironment.

PubMed 2022/02/25(内容时间) Biosci Rep Q2 · IF 4.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

提出的 AS 特征是一种有前景的生物标志物,可用于评估 OV 的总生存期(OS)。AS 事件特征与肿瘤免疫微环境相结合,使人们对 OV 患者的免疫状态有了更深入的了解,也为探索新的预后预测因子和精准治疗方法提供了新的见解。

研究思路结论见上方概要

卵巢癌(OV)严重威胁女性健康。免疫治疗是一种新方法。信使RNA(mRNA)的可变剪接(AS)及其调控与理解每一个癌症标志高度相关,并可能提供更广泛的靶点空间。

我们从癌症基因组图谱(TCGA)数据库下载了587个肿瘤组织的临床信息和mRNA表达谱。我们构建了一个风险评分模型来预测OV患者的预后。进一步探讨了基于AS的聚类与肿瘤免疫微环境特征之间的关联。还根据风险评分分组对每个OV样本进行了ESTIMATE算法。共筛选出三个与风险评分显著相关的免疫检查点基因。

AS事件是OV队列中可靠且稳定的独立风险预测因子。高风险评分组患者预后较差(P<0.001)。活化的肥大细胞、静息的NK细胞和中性粒细胞与风险评分呈正相关。低风险评分组中M1型巨噬细胞数量也更多(P<0.05)。检查点基因CD274、CTLA-4和PDCD1LG2与OV中AS的风险评分呈负相关。

展开英文摘要原文

Ovarian cancer (OV) is a serious threat to women's health. Immunotherapy is a new approach. Alternative splicing (AS) of messenger RNA (mRNA) and its regulation are highly relevant for understanding every cancer hallmark and may offer a broadened target space.

We downloaded the clinical information and mRNA expression profiles of 587 tumor tissues from The Cancer Genome Atlas (TCGA) database. We constructed a risk score model to predict the prognosis of OV patients. The association between AS-based clusters and tumor-immune microenvironment features was further explored. The ESTIMATE algorithm was also carried out on each OV sample depending on the risk score groups. A total of three immune checkpoint genes that have a significant correlation with risk scores were screened.

The AS-events were a reliable and stable independent risk predictor in the OV cohort. Patients in the high-risk score group had a poor prognosis (P<0.001). Mast cells activated, NK cells resting, and Neutrophils positively correlated with the risk score. The number of Macrophages M1 was also more numerous in the low-risk score group (P<0.05). Checkpoint genes CD274, CTLA-4, and PDCD1LG2, showed a negative correlation with the risk score of AS in OV.

The proposed AS signature is a promising biomarker for estimating overall survival (OS) in OV. The AS-events signature combined with tumor-immune microenvironment enabled a deeper understanding of the immune status of OV patients, and also provided new insights for exploring novel prognostic predictors and precise therapy methods.

论文信息

作者
Sun D、Zhao X、Yu Y、Li W、Gu P、Zhi Z、Xu D
单位
Department of Gynecology, Third Xiangya Hospital of Central South University, Changsha 410013, Hunan, China.China
文献类型
非美国政府资助研究
期刊
Bioscience reports2022 Feb 25
原文标识
PubMed 35137909 · DOI 10.1042/BSR20212090